It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Since late 2019, the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resultant spread of COVID-19 have given rise to a worldwide health crisis that is posing great challenges to public health and clinical treatment, in addition to serving as a formidable threat to the global economy. To obtain an effective tool to prevent and diagnose viral infections, we attempted to obtain human antibody fragments that can effectively neutralize viral infection and be utilized for rapid virus detection. To this end, several human monoclonal antibodies were isolated by bio-panning a phage-displayed human antibody library, Tomlinson I. The selected clones were demonstrated to bind to the S1 domain of the spike glycoprotein of SARS-CoV-2. Moreover, clone A7 in Fab and IgG formats were found to effectively neutralize the binding of S protein to angiotensin-converting enzyme 2 in the low nM range. In addition, this clone was successfully converted to quench-based fluorescent immunosensors (Quenchbodies) that allowed antigen detection within a few minutes, with the help of a handy fluorometer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Weifang Medical University, Weifang Key Laboratory for Antibodies Medicine, School of Life Science and Technology, Weifang, China (GRID:grid.268079.2) (ISNI:0000 0004 1790 6079)
2 Tokyo Institute of Technology, Laboratory for Chemistry and Life Science, Institute of Innovative Research, Yokohama, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105)
3 Peking University, School of Basic Medical Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)
4 Weifang Medical University, Weifang Key Laboratory for Antibodies Medicine, School of Life Science and Technology, Weifang, China (GRID:grid.268079.2) (ISNI:0000 0004 1790 6079); Tokyo Institute of Technology, Laboratory for Chemistry and Life Science, Institute of Innovative Research, Yokohama, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105); Tokyo Institute of Technology, World Research Hub Initiative (WRHI), Institute of Innovative Research, Yokohama, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105); University of Health and Rehabilitation Sciences, School of Rehabilitation Sciences and Engineering, Qingdao, China (GRID:grid.32197.3e)
5 Tokyo Institute of Technology, Laboratory for Chemistry and Life Science, Institute of Innovative Research, Yokohama, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105); Tokyo Institute of Technology, World Research Hub Initiative (WRHI), Institute of Innovative Research, Yokohama, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105)